Effectiveness of pimobendan in cats with cardiogenic arterial thromboembolism
DOI:
https://doi.org/10.31548/dopovidi5(105).2023.017Keywords:
congestive heart failure, hypertrophic cardiomyopathy, paresis, pulmonary edema, survivalAbstract
Cardiogenic arterial thromboembolism (CATE) is a common complication of cardiomyopathy in cats. Current research is aimed at developing effective protocols for the therapy and prevention of CATE. The main focus is on finding effective anticoagulants, antiaggregants, and methods that improve blood supply to the affected area. At the same time, interest in the use of pimobendan for the therapy of congestive heart failure in cats has increased among researchers. Published works show an increase in life expectancy in cats with hypertrophic cardiomyopathy (HCM) and a positive effect on left atrial function. Therefore, the study of the effect of pimobendan on life expectancy, the occurrence of relapses in cats according to CATE is relevant and became the goal of this work. The study included 24 animals that had a CATE incident due to HCM and lived more than 2 weeks after the crisis. Two groups were formed: the first - 13 cats that after stabilization of the condition received standard therapy (furosemide, ACE inhibitor, clopidogrel) and pimobendan; the second - 11 cats that received only standard therapy. The anamnesis, clinical examination, echocardiographic examination, and information about relapse, death or euthanasia were recorded in the animals. 91.7% of cats were males, the average age was 7 ± 0.7 years. Dyspnoea, pulmonary edema, hypothermia, change in mental status, paresis and anemia of the affected limb were found in the majority. Two pelvic limbs were more often affected. Relapse occurred in 37.5% of subjects. The time interval from the incident to the recurrence in the first group was 387.4 ± 104.5 and in the second 107.2 ± 32.1 days. Euthanasia was performed for 20.8% of animals and was always associated with relapse. The survival time in the first group averaged 403.7 ± 104.0, and in the second - 314 ± 47.3 days. The median survival time for the first group is 9.5 months and for the second 12.5. After the death of all the animals in the first group, 40% of cats who received pimobendan remained alive. We didn`t find statistical differences between the groups in the number of relapses, euthanasias, duration of life and survival. Was found a significant difference in the length of time before relapse. Pimobendan did not show a negative effect on life expectancy in cats according to CATE. The positive effect is probably not clear enough and needs to be studied in a larger cohort of animals.
References
Borgeat, K., Wright, J., Garrod, O., Payne, J. R., & Fuentes, V. L. (2014). Arterial thromboembolism in 250 cats in general practice: 2004–2012. Journal of Veterinary Internal Medicine, 28 (1), 102–108. http://doi.org/10.1111/jvim.12249
Den Toom, M. L., van Leeuwen, M. W., Szatmari, V., & Teske, E. (2017). Effects of clopidogrel therapy on whole blood platelet aggregation, the Plateletworks ® assay and coagulation parameters in cats with asymptomatic hypertrophic cardiomyopathy: a pilot study. The veterinary quarterly, 37 (1), 8–15. http://doi.org/10.1080/01652176.2016.1244618
Duler, L., Scollan, K. F., & LeBlanc, N. L. (2019). Left atrial size and volume in cats with primery cardiomyopathy with and without congestive heart failure. Journal of veterinary cardiology, 24, 36–47. http://doi.org/10.1016/j.jvc.2019.04.003
Fox, P. R., Keene, B. W., Lamb, K., Schober, K. A., Chetboul, V…. Ohara, V. Y. T. (2018). Internetional collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently cats: the REVAL study. Journal of Veterinary Internal Medicine, 32(3), 930-943. http://doi.org/10.1111/jvim.15122
Fuentes, V. L., Abbott, J., Chetboul, V., Cote, E., Fox, P. R., Häggström, J., Kittleson, M. D., Schober, K., & Stern, J. A. (2020). ACVM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats. Journal of Veterinary Internal Medicine, 34 (3), 1062–1077. http://doi.org/10.1111/jvim.15745
Hassan, M. H., Abu-Seida, A. M., Torad, F. A., & Hassan, E. A. (2020). Feline aortic thromboembolism: presentation, diagnosis, and treatment outcomes of 15 cats. Open veterinary journal, 10 (3), 340–346. http://doi.org/10.4314/ovj.v10i3.13
Hogan, D. F. (2017). Feline cardiogenic arterial thromboembolism. Veterinary Clinics of North America: Small Animal Practice, 47 (5), 1065–1082. http://doi.org/10.1016/j.cvsm.2017.05.001
Hogan, D. F., Fox, P. R., Jacob, K., Keene, B., Laste, N. J., Rosenthal, S., Sederquist, K., & Weng, H. -Y. (2015). Secondary prevention of cardiogenic arterial thromboembolism in the cat: The double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT). Journal of Veterinary Cardiology, 17, 306–317, http://doi.org/10.1016/j.jvc.2015.10.004
Kittleson, M.D., & Cote, E. (2021). The feline cardiomyopathies: 1. General concepts. Journal of feline medicine and surgery, 23 (11), 1009–10027. http://doi.org/10.1177/1098612X211021819
Kochie, S. L., Schober, K. E., Rhineheart, J., Winter, R. L., Bonagura, J. D., Showers, A., & Yildes, V. (2021). Effects of pimobendan on left atrial transport function in cats. Journal of Veterinary Internal Medicine, 35 (1), 10–21. http://doi.org/10.1111/jvim.15976
Kostiuk, O.S., & Maryniuk, M.P. (2019). Papillary muscle evaluation in healthy cats and cats with hypertrophic cardiomyopathy. Ukrainian Journal of Veterinary Sciences, 9 (3), 88-94, http://doi.org/10.31548/ujvs2019.03.013
Lo, S. T., Walker, A. L., Georges, C. J., Li, R. H. L., & Stern, J. A. (2022). Dual therapy with clopidogrel and rivaroxaban in cats with thromboembolic disease. Journal of Feline Medicine and Surgery, 24 (4), 277–283. http://doi.org/10.1177/1098612X211013736
Matos, J.N., Payne, J.R., Seo, J., & Fuentes, V.L. (2022). Natural history of hypertrophic cardiomyopathy in cats from rehoming centers: The CatScan II study. Journal of Veterinary Internal Medicine, 36 (6), 1900–1912. http://doi.org/10.1111/jvim.16576
Mitropoulou, A., Hassdenteufel, E., Lin, J., Bauer, N., Wurtinger, G., Vollmar, C., Henrich, E., Hildebrandt, N., & Schneider, M. (2022). Retrospective evaluation of intravenous enoxaparin administration in feline arterial thromboembolism. Animals (Basel), 12 (15), 1977. http://doi.org/10.3390/ani12151977
Oldach, M. S., Ueda, Y., Ontiveros, E. S., Fousse, S. L., Visser, L. C., & Stern, J., A. (2021). Acute pharmacodynamics effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy. BMC Veterinary Research, 17 (1), 89. http://doi.org/10.1186/s12917-021-02799-9
Payne, J. R., Borgeat, K., Brodbelt, D. C., Connolly, D. J., & Luis Fuentes, V. (2015). Risk factors associated with sudden death vs. congestive heart failure or arterial thromboembolism in cats with hypertrophic cardiomyopathy. Journal of Veterinary Cardiology, 17, 318–328. http://doi.org/10.1016/j.jvc.2015.09.008
Petrushko, A., & Grushanska, N. (2022). Prevalence of feline cardiomyopathy phenotypes and arterial thromboembolism. ScienceRise: Biological Science, 4 (33), 35–43. http://doi.org/10.15587/2519-8025.2022.271011
Reina-Doreste, Y., Stern, J. A., Keene, B. W., Tou, S. P., Atkins, C. E., DeFrancesco T. C., Ames, M. K., Hodge, T. E., & Meurs, K. M. (2014). Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. Journal of the American Veterinary Medical Association, 245 (5), 534–539. http://doi.org/10.2460/javma.245.5.534
Schober, K. E., Rush, J. E., Fuentos, V. L., Glaus, T., Summerfrield, N. J., Wright, K., Lehmkuhl, L., Wess, G., Sayer, M. P., Loureiro, J., MacGregor, J., & Mohren, N. (2021). Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. Journal of Veterinary Internal Medicine, 35 (2), 789–800. http://doi.org/10.1111/jvim.16054
Schoeman, J. P. (1999). Feline distal aortic thromboembolism: a review of 44 cases (1990–1998). Journal of Feline Medicine and Surgery, 1 (4), 221–231. http://doi.org/10.1053/jfms.1999.0049
Sharp, C. R., Blais, M. C., Boyd, C. J., Brainard, B. M., Chan, D. L., de Laforcade, A., Goggs, R., Guillaumin, J., Lynch, A., Mays, E., McBride, D., Rosati, T., & Rozanski, E. A. (2022). 2022 Update of the consensus on the rational use of antithrombotics an thrombolytics in veterinary critical care (CURATIVE) Domain 6: Defining rational use of thrombolytics. Journal of veterinary emergency and critical care (San Antonio, Tex.: 2001), 32 (4), 446–470. http://doi.org/10.1111/vec.13227
Spalla, I., Boswood, A., Connolly, D.J., & Fuentes, V.L. (2019). Speckle tracking echocardiography in cats with preclinical hypertrophic cardiomyopathy. Journal of Veterinary Internal Medicine, 33 (3), 1232–1241. http://doi.org/10.1111/jvim.15495
Tosuwan, J., Surachetpong, S. D., & Hunprasit, V. (2023). Assessment of left atrial myocardial deformation using two-dimensional speckle-tracking echocardiography in cats with cardiogenic and non-cardiogenic arterial thromboembolism. Internal Journal of Veterinary Science & Medicine, 11 (1), 11–22. http://doi.org/10.1080/23144599.2023.2196853
Downloads
Additional Files
- ТЕРАПЕВТИЧНА ЕФЕКТИВНІСТЬ ПІМОБЕНДАНУ ЗА КАРДІОГЕННОЇ АРТЕРІАЛЬНОЇ ТРОМБОЕМБОЛІЇ У КОТІВ (Українська)
- ТЕРАПЕВТИЧНА ЕФЕКТИВНІСТЬ ПІМОБЕНДАНУ ЗА КАРДІОГЕННОЇ АРТЕРІАЛЬНОЇ ТРОМБОЕМБОЛІЇ У КОТІВ (Українська)
- ТЕРАПЕВТИЧНА ЕФЕКТИВНІСТЬ ПІМОБЕНДАНУ ЗА КАРДІОГЕННОЇ АРТЕРІАЛЬНОЇ ТРОМБОЕМБОЛІЇ У КОТІВ (Українська)
Published
Issue
Section
License
Relationship between right holders and users shall be governed by the terms of the license Creative Commons Attribution – non-commercial – Distribution On Same Conditions 4.0 international (CC BY-NC-SA 4.0):https://creativecommons.org/licenses/by-nc-sa/4.0/deed.uk
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
